Allogene Therapeutics is a biotechnology business based in the US. Allogene Therapeutics shares (ALLO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.85 – an increase of 8.78% over the previous week. Allogene Therapeutics employs 232 staff and has a trailing 12-month revenue of around $65,000.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.85 |
|---|---|
| 52-week range | $2.01 - $5.78 |
| 50-day moving average | $2.63 |
| 200-day moving average | $3.22 |
| Wall St. target price | $9.59 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.59 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.71 from 2024-10-15
| 1 week (2024-10-10) | 3.44% |
|---|---|
| 1 month (2024-09-17) | -5.90% |
| 3 months (2024-07-17) | -20.76% |
| 6 months (2024-04-17) | -22.79% |
| 1 year (2023-10-17) | -15.05% |
|---|---|
| 2 years (2022-10-17) | -73.61% |
| 3 years (2021-10-13) | N/A |
| 5 years (2019-10-17) | 27.78 |
| Revenue TTM | $65,000 |
|---|---|
| Gross profit TTM | $243,000 |
| Return on assets TTM | -23.88% |
| Return on equity TTM | -49.11% |
| Profit margin | 0% |
| Book value | $2.46 |
| Market Capitalization | $566.7 million |
TTM: trailing 12 months
We're not expecting Allogene Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Allogene Therapeutics's shares have ranged in value from as little as $2.01 up to $5.775. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Allogene Therapeutics's is 0.832. This would suggest that Allogene Therapeutics's shares are less volatile than average (for this exchange).
Allogene Therapeutics, Inc. , a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18. 2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.